---
title: "The FDA warns that Novo Nordisk has not reported side effects or death cases related to the weight loss drug Ozempic"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278580386.md"
description: "Novo Nordisk AS received a warning letter from the FDA for failing to report all suspected side effects of the weight loss drug Ozempic. The letter mentioned two cases of death and one case of suicide, with patients all receiving treatment with semaglutide. The FDA did not explicitly state whether these events were related to the drug. The stock recently fell by 3%"
datetime: "2026-03-10T14:45:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278580386.md)
  - [en](https://longbridge.com/en/news/278580386.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278580386.md)
generator: "portal-rs"
---

# The FDA warns that Novo Nordisk has not reported side effects or death cases related to the weight loss drug Ozempic

Novo Nordisk AS (NVO.US) received a warning letter from the U.S. Food and Drug Administration (FDA) for failing to report all suspected side effects experienced by patients taking its blockbuster weight loss drug Ozempic. The stock price has recently dropped by 3%.

The FDA's letter indicated that the cases included two deaths and one suicide, with patients having received treatment with semaglutide, the generic name for Ozempic and Wegovy. The FDA did not explicitly state whether these deaths or other side effects were related to the drug

### Related Stocks

- [600110.CN](https://longbridge.com/en/quote/600110.CN.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

- [Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can](https://longbridge.com/en/news/296711443.md)
- [Mitsui to supply e-methanol to OMV for land transport fuel under RFNBO deal](https://longbridge.com/en/news/296423772.md)
- [Novo's top US exec wants more insurance coverage for weight-loss drugs](https://longbridge.com/en/news/290802441.md)
- [Ozempic developer has replaced the needle with a simple pill - so why is it failing to impress?](https://longbridge.com/en/news/294956526.md)
- [Brazil approves first generic semaglutide pen after Ozempic patent expiry](https://longbridge.com/en/news/287657832.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**